Sciex, Hepregen Team up on Metabolite Identification Offering
News May 21, 2015
Sciex and Hepregen today announced that they have signed a co-marketing agreement, under which the companies will bundle certain of their technologies together as a metabolite identification (MetID) solution for drug metabolism researchers.
The new offering centers around Hepregen's HepatoPac kit, an in vitro liver model comprising cryopreserved primary hepatocytes from a human, rat, monkey, or dog that are micropatterned onto microwell plates. It also includes Sciex's TripleTOF 6600 LC-MS system, as well as its Swath Acquisition data-capture method and MetabolitePilot software.
Specific terms of the arrangement were not disclosed.
"Until now, particularly in the case of low-turnover compounds, drug metabolism researchers have had significant difficulty predicting in vitro metabolic outcomes with complete confidence," Joe Fox, senior director of Sciex's pharma business, said in a statement. "Together with Hepregen, we have established this much needed end-to-end solution for our MetID customers."
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE